Analysis of individual case safety reports of drug-induced anaphylaxis to the Korea Adverse Event Reporting System
- Author:
Min Kyoung CHO
1
;
Mira MOON
;
Hyun Hwa KIM
;
Dong Yoon KANG
;
Ju Yeun LEE
;
Sang Heon CHO
;
Hye Ryun KANG
Author Information
- Publication Type:Original Article
- Keywords: Drug-induced anaphylaxis; Pharmacovigilance; Drug labeling; Mortality rate
- MeSH: Anaphylaxis; Anti-Bacterial Agents; Antineoplastic Agents; Demography; Drug Labeling; Female; Humans; Korea; Mortality; Pharmacovigilance; United States Food and Drug Administration
- From:Allergy, Asthma & Respiratory Disease 2020;8(1):30-35
- CountryRepublic of Korea
- Language:Korean
- Abstract: PURPOSE: To identify causative agents of the drug-induced anaphylaxis (DIA) by using the Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System (KIDS-KAERS) database (Ministry of Food and Drug Safety) in Korea and to check their labeling information regarding anaphylaxis.METHODS: Among Individual Case Safety Reports from January, 2008 to December 2017, cases of DIA were analyzed for demographics, causative agents and fatal cases resulting in death. The domestic drug labeling, Micromedex and U.S. Food and Drug Administration (FDA) drug package insert, were reviewed to check if the labeling information on suspected causative agents contains anaphylaxis.RESULTS: A total of 4,700 cases of DIA were analyzed. The mean age was 49.85±18.32 years, and 2,642 patients (56.2%) were females. Among 8,664 drugs reported as causative agents, antibiotics (27.4%) accounted for the largest portion. There were 18 fatal cases: antibiotics (7 cases), antineoplastic agents (4 cases) were the major causative drugs for the mortality cases. Of 513 drugs reported as suspected causative agents, 103 (20.1%) did not list anaphylaxis as an adverse effect on domestic drug labeling and 16 (3.1%) did not reflect anaphylaxis in any of 3 adverse drug information.CONCLUSION: Analysis of 10-year data showed that antibiotics were the main cause of DIA and the mortality rate was 0.7%. In 3.1% of suspected drugs, there was no description of anaphylaxis in any of the drug labeling.
